An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 3, Pages 275-285
Publisher
Informa UK Limited
Online
2019-12-03
DOI
10.1080/14656566.2019.1695779
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non‐surgical and bariatric surgery patients
- (2019) Mohamed Suliman et al. DIABETES OBESITY & METABOLISM
- Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood
- (2019) Amit V. Khera et al. CELL
- Liraglutide in Children and Adolescents with Type 2 Diabetes
- (2019) William V. Tamborlane et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL‐IBT Program
- (2019) Thomas A. Wadden et al. Obesity
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Obesity Pharmacotherapy
- (2018) Katherine H. Saunders et al. MEDICAL CLINICS OF NORTH AMERICA
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- The epidemiology of obesity
- (2018) Yu Chung Chooi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetics and epigenetics in obesity
- (2018) Kerstin Rohde et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
- (2017) Philip R. Schauer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms, Pathophysiology, and Management of Obesity
- (2017) Steven B. Heymsfield et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects
- (2016) Harold Bays et al. CURRENT MEDICAL RESEARCH AND OPINION
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Response to Comment on Crews et al. Role and Determinants of Adherence to Off-loading in Diabetic Foot Ulcer Healing: A Prospective Investigation. Diabetes Care 2016;39:1371–1377
- (2016) Ryan T. Crews et al. DIABETES CARE
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
- (2016) J. Ard et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
- (2016) Brian Tomlinson et al. Expert Opinion on Drug Metabolism & Toxicology
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
- (2015) Lisbeth V. Jacobsen et al. CLINICAL PHARMACOKINETICS
- Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points
- (2015) Daisuke Yabe et al. CURRENT MEDICAL RESEARCH AND OPINION
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Liraglutide: A Review of Its Use in the Management of Obesity
- (2015) Lesley J. Scott DRUGS
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Incretin Therapy and Pancreatic Pathologies: Background Pathology Versus Drug-Induced Pathology in Rats
- (2014) J. M. Egan et al. DIABETES
- Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
- (2014) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide in the treatment of obesity
- (2014) Sarah Yoon Ai Ng et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Potential side effects to GLP-1 agonists: understanding their safety and tolerability
- (2014) Agostino Consoli et al. Expert Opinion On Drug Safety
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
- (2014) Assumpta Caixas et al. Drug Design Development and Therapy
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults
- (2013) M E J Lean et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Liraglutide for type 2 diabetes mellitus
- (2011) Ram Kela et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mild Renal Impairment and the Efficacy and Safety of Liraglutide
- (2010) Jaime Davidson et al. Endocrine Practice
- Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide
- (2010) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide
- (2009) Lisbeth V. Jacobsen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog
- (2009) Jerry Meece PHARMACOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now